Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal

Impact · against what's priced in

PTGX is shifting from a clinical-stage biotech to a royalty-generating entity following the approval of ICOTYDE and the priority review of rusfertide. The strong cash position and capital-light model significantly lower the risk of dilution through 2028.

PTGX+0.70: No priced-in read yet
In context: The FDA approval of ICOTYDE and the Priority Review for rusfertide move the company from clinical binary risk to execution risk, supported by $620M in cash.
Read from the article alone

Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal

biotech
PTGX
clinical trials
fda approval
milestones
pharma
priority review
royalties

Search tags

Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal

What matters in this story

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal

What matters in this story

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

How each ticker is affected

Track these names every morning.

iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal

What matters in this story

Next reads from the same story arc

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal

What matters in this story

Next reads from the same story arc

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

How each ticker is affected

Track these names every morning.

iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track